Wren Therapeutics completes £18 million Series A financing

Dublin-Ireland, 22 January 2019: Malin Corporation plc (ISE:MLC), a company investing in highly innovative life sciences companies, notes the completion of an £18 million Series A financing round by Wren Therapeutics Limited (“Wren”), a biopharmaceutical drug discovery company based in Cambridge, UK and one of Malin’s early-stage growth potential assets.

Read the full press releaseCompany website